Observations placeholder

Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.

Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).

Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin

Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.

On Jan, 21, 2016: 234 people reported to have side effects when taking Ocuflox. Among them, 3 people (1.28%) have Hallucination.

On Jan, 19, 2016: 3,273 people reported to have side effects when taking Ofloxacin. Among them, 22 people (0.67%) have Hallucination.

Time on Ofloxacin when people have Hallucination  :

 On Jan, 11, 2016: 3,273 people reported to have side effects when taking Ofloxacin. Among them, 29 people (0.89%) have Death.

Time on Ofloxacin when people have Death  :

 On Jan, 9, 2016: 234 people reported to have side effects when taking Ocuflox. Among them, 5 people (2.14%) have Death.